{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T20:12:31Z","timestamp":1751400751545,"version":"3.37.3"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2024,4,25]],"date-time":"2024-04-25T00:00:00Z","timestamp":1714003200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,4,25]],"date-time":"2024-04-25T00:00:00Z","timestamp":1714003200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Breast Cancer Res Treat"],"published-print":{"date-parts":[[2024,8]]},"DOI":"10.1007\/s10549-024-07302-0","type":"journal-article","created":{"date-parts":[[2024,4,25]],"date-time":"2024-04-25T17:02:29Z","timestamp":1714064549000},"page":"473-481","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Perspectives on shorter durations of anti-HER2 therapy in early-stage HER2-positive breast cancer: a patient survey"],"prefix":"10.1007","volume":"206","author":[{"given":"M.","family":"Bradbury","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"MF","family":"Savard","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Stober","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L.","family":"Clemons","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Clemons","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"Hilton","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G.","family":"Pond","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L.","family":"Vandermeer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0323-6372","authenticated-orcid":false,"given":"SF","family":"McGee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,4,25]]},"reference":[{"key":"7302_CR1","doi-asserted-by":"publisher","unstructured":"Omarini C et al (2022) Jul., T-DM1 efficacy in trastuzumab-pertuzumab pre-treated HER2 positive metastatic breast cancer patients: a meta-analysis, vol. 22, [Online]. Available: https:\/\/bmccancer.biomedcentral.com\/articles\/https:\/\/doi.org\/10.1186\/s12885-022-09556-7","DOI":"10.1186\/s12885-022-09556-7"},{"key":"7302_CR2","doi-asserted-by":"publisher","unstructured":"Joensuu H et al (2018) Sep., Effect of Adjuvant Trastuzumab for a Duration of 9 Weeks vs 1 Year With Concomitant Chemotherapy for Early Human Epidermal Growth Factor Receptor 2\u2013Positive Breast Cancer, JAMA Oncol, vol. 4, no. 9, pp. 1199\u20131206, https:\/\/doi.org\/10.1001\/jamaoncol.2018.1380","DOI":"10.1001\/jamaoncol.2018.1380"},{"key":"7302_CR3","doi-asserted-by":"publisher","unstructured":"Slamon D et al (2011) Oct., Adjuvant Trastuzumab in HER2-Positive Breast Cancer, N. Engl. J. Med, vol. 365, no. 14, pp. 1273\u20131283, https:\/\/doi.org\/10.1056\/NEJMoa0910383","DOI":"10.1056\/NEJMoa0910383"},{"key":"7302_CR4","unstructured":"Piccart-Gebhart MJ, Procter M, Leyland-Jones B, Goldhirsch A Trastuzumab after Adjuvant Chemotherapy in HER2-Positive Breast Cancer | NEJM. Accessed: Nov. 07, 2022. [Online]. Available: https:\/\/www.nejm.org\/doi\/10.1056\/NEJMoa052306?url_ver=Z39.88-2003&_id=ori:rid:crossref.org&_dat=cr_pub%20%200www.ncbi.nlm.nih.gov"},{"key":"7302_CR5","doi-asserted-by":"publisher","unstructured":"Romond EH et al (2005) Oct., Trastuzumab plus Adjuvant Chemotherapy for Operable HER2-Positive Breast Cancer, N. Engl. J. Med, vol. 353, no. 16, pp. 1673\u20131684, https:\/\/doi.org\/10.1056\/NEJMoa052122","DOI":"10.1056\/NEJMoa052122"},{"key":"7302_CR6","doi-asserted-by":"publisher","unstructured":"Moja L et al (2012) Trastuzumab containing regimens for early breast cancer, Cochrane Database Syst. Rev, vol. no. 4, p. CD006243, Apr. 2012, https:\/\/doi.org\/10.1002\/14651858.CD006243.pub2","DOI":"10.1002\/14651858.CD006243.pub2"},{"key":"7302_CR7","doi-asserted-by":"publisher","unstructured":"Conte P et al (2018) Dec., Nine weeks versus 1 year adjuvant trastuzumab in combination with chemotherapy: final results of the phase III randomized Short-HER study\u2021, Ann. Oncol, vol. 29, no. 12, pp. 2328\u20132333, https:\/\/doi.org\/10.1093\/annonc\/mdy414","DOI":"10.1093\/annonc\/mdy414"},{"key":"7302_CR8","unstructured":"Mavroudis D, Saloustros E, Malamos N, Kakolyris S, study by the Hellenic Oncology Research Group (HORG) Six versus 12 months of adjuvant trastuzumab in combination with dose-dense chemotherapy for women with HER2-positive breast cancer: a multicenter randomized - Annals of Oncology. Accessed: Nov. 07, 2022. [Online]. Available: https:\/\/www.annalsofoncology.org\/article\/S09237534(19)34520-X\/fulltext"},{"key":"7302_CR9","doi-asserted-by":"publisher","unstructured":"Earl HM et al (2019) Jun., 6 versus 12 months of adjuvant trastuzumab for HER2-positive early breast cancer (PERSEPHONE): 4-year disease-free survival results of a randomised phase 3 non-inferiority trial, Lancet Lond. Engl, vol. 393, no. 10191, pp. 2599\u20132612, https:\/\/doi.org\/10.1016\/S0140-6736(19)30650-6","DOI":"10.1016\/S0140-6736(19)30650-6"},{"key":"7302_CR10","doi-asserted-by":"publisher","unstructured":"Pivot X et al (2019) Jun., 6 months versus 12 months of adjuvant trastuzumab in early breast cancer (PHARE): final analysis of a multicentre, open-label, phase 3 randomised trial, The Lancet, vol. 393, no. 10191, pp. 2591\u20132598, https:\/\/doi.org\/10.1016\/S0140-6736(19)30653-1","DOI":"10.1016\/S0140-6736(19)30653-1"},{"key":"7302_CR11","doi-asserted-by":"crossref","unstructured":"Conte P, Guarneri V, Bisagni G, Piacentini F, Brandes AA et al (2018) Congress 9 weeks versus 1 year adjuvant trastuzumab for HER2\u2009+\u2009early breast cancer: subgroup analysis of the ShortHER trial allows to identify patients for whom a shorter trastuzumab administration may have a favourable risk\/benefit ratio, presented at the ESMO 2018","DOI":"10.1093\/annonc\/mdy424.005"},{"key":"7302_CR12","doi-asserted-by":"publisher","unstructured":"Conte PF et al (2023) Jun., Nine-weeks versus one-year trastuzumab for early-stage HER2\u2009+\u2009breast cancer: 10-year update of the Short-HER phase III randomized trial., J. Clin. Oncol, vol. 41, no. 17_suppl, pp. LBA637\u2013LBA637, https:\/\/doi.org\/10.1200\/JCO.2023.41.17_suppl.LBA637","DOI":"10.1200\/JCO.2023.41.17_suppl.LBA637"},{"key":"7302_CR13","unstructured":"NCCN (2023) National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology. Breast Cancer. Version 4.2023. Mar. 23"},{"key":"7302_CR14","doi-asserted-by":"publisher","unstructured":"Cardoso F et al (2019) Aug., Early breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up\u2020, Ann. Oncol, vol. 30, no. 8, pp. 1194\u20131220, https:\/\/doi.org\/10.1093\/annonc\/mdz173","DOI":"10.1093\/annonc\/mdz173"},{"key":"7302_CR15","doi-asserted-by":"publisher","unstructured":"Denduluri N et al (2021) Feb., Selection of Optimal Adjuvant Chemotherapy and Targeted Therapy for Early Breast Cancer: ASCO Guideline Update, J. Clin. Oncol, vol. 39, no. 6, pp. 685\u2013693, https:\/\/doi.org\/10.1200\/JCO.20.02510","DOI":"10.1200\/JCO.20.02510"},{"key":"7302_CR16","doi-asserted-by":"publisher","unstructured":"Basulaiman B et al (Aug. 2019) Creating a pragmatic trials program for breast cancer patients: rethinking clinical trials (REaCT). Breast Cancer Res Treat 177(1):93\u2013101. https:\/\/doi.org\/10.1007\/s10549-019-05274-0","DOI":"10.1007\/s10549-019-05274-0"},{"key":"7302_CR17","doi-asserted-by":"publisher","unstructured":"Eysenbach G (Sep. 2004) Improving the quality of web surveys: the Checklist for reporting results of internet E-Surveys (CHERRIES). J Med Internet Res 6(3):e34. https:\/\/doi.org\/10.2196\/jmir.6.3.e34","DOI":"10.2196\/jmir.6.3.e34"},{"key":"7302_CR18","doi-asserted-by":"publisher","unstructured":"Cameron D et al (Mar. 2017) 11 years\u2019 follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive early breast cancer: final analysis of the HERceptin adjuvant (HERA) trial. Lancet Lond Engl 389(10075):1195\u20131205. https:\/\/doi.org\/10.1016\/S0140-6736(16)32616-2","DOI":"10.1016\/S0140-6736(16)32616-2"},{"key":"7302_CR19","doi-asserted-by":"crossref","unstructured":"Earl HM, Hiller L, Dunn JA, Conte P, D\u2019Amico R et al (2021) LBA11 - Individual patient data meta-analysis of 5 non-inferiority RCTs of reduced duration single agent adjuvant trastuzumab in the treatment of HER2 positive early breast cancer, presented at the ESMO Congress, 2021","DOI":"10.1016\/j.annonc.2021.08.2083"},{"key":"7302_CR20","doi-asserted-by":"publisher","unstructured":"Suter TM et al (Sep. 2016) Trastuzumab-Associated Cardiac adverse effects in the Herceptin Adjuvant Trial. J Clin Oncol. https:\/\/doi.org\/10.1200\/JCO.2006.09.1611","DOI":"10.1200\/JCO.2006.09.1611"},{"key":"7302_CR21","doi-asserted-by":"publisher","unstructured":"Debien V et al (2023) Aug., DECRESCENDO: de-escalating chemotherapy in HER2-positive, estrogen receptor-negative, node-negative early breast cancer, Future Oncol. Lond. Engl, vol. 19, no. 24, pp. 1655\u20131667, https:\/\/doi.org\/10.2217\/fon-2022-1282","DOI":"10.2217\/fon-2022-1282"},{"key":"7302_CR22","doi-asserted-by":"publisher","unstructured":"Macpherson I et al (2022) Feb., Abstract OT2-05-01: The HER2-RADiCAL study (Response ADaptive CAre pLan) - Tailoring treatment for HER2 positive early breast cancer, Cancer Res, vol. 82, no. 4_Supplement, pp. OT2-05-01, https:\/\/doi.org\/10.1158\/1538-7445.SABCS21-OT2-05-01","DOI":"10.1158\/1538-7445.SABCS21-OT2-05-01"},{"key":"7302_CR23","doi-asserted-by":"publisher","unstructured":"Eiger D et al (Feb. 2020) Cardiotoxicity of trastuzumab given for 12 months compared to shorter treatment periods: a systematic review and meta-analysis of six clinical trials. ESMO Open 5(1):e000659. https:\/\/doi.org\/10.1136\/esmoopen-2019-000659","DOI":"10.1136\/esmoopen-2019-000659"},{"key":"7302_CR24","doi-asserted-by":"publisher","unstructured":"Bradbury M et al (2023) Dec., Shorter Durations of Anti-HER2 Therapy for Patients with Early-Stage, HER2-Positive Breast Cancer: The Physician Perspective, Curr. Oncol. Tor. Ont, vol. 30, no. 12, pp. 10477\u201310487, https:\/\/doi.org\/10.3390\/curroncol30120763","DOI":"10.3390\/curroncol30120763"},{"key":"7302_CR25","doi-asserted-by":"publisher","unstructured":"Niraula S, Gyawali B (Jan. 2019) Optimal duration of adjuvant trastuzumab in treatment of early breast cancer: a meta-analysis of randomized controlled trials. Breast Cancer Res Treat 173(1):103\u2013109. https:\/\/doi.org\/10.1007\/s10549-018-4967-8","DOI":"10.1007\/s10549-018-4967-8"},{"key":"7302_CR26","doi-asserted-by":"publisher","unstructured":"Booth CM et al (Aug. 2023) Common sense oncology: outcomes that matter. Lancet Oncol 24(8):833\u2013835. https:\/\/doi.org\/10.1016\/S1470-2045(23)00319-4","DOI":"10.1016\/S1470-2045(23)00319-4"},{"key":"7302_CR27","doi-asserted-by":"publisher","unstructured":"Freedman RA et al (2022) Dec., Breast cancer knowledge and understanding treatment rationales among diverse breast cancer survivors, Breast Cancer Res. Treat, vol. 196, no. 3, pp. 623\u2013633, https:\/\/doi.org\/10.1007\/s10549-022-06752-8","DOI":"10.1007\/s10549-022-06752-8"},{"key":"7302_CR28","unstructured":"REaCT : REthinking Clinical Trials. Accessed: Jan. 11, 2024. [Online]. Available: https:\/\/react.ohri.ca\/react-her-time\/"},{"key":"7302_CR29","doi-asserted-by":"publisher","unstructured":"Wang H, Yee D (2019) I-SPY 2: a Neoadjuvant Adaptive Clinical Trial Designed to Improve Outcomes in High-Risk Breast Cancer, Curr. Breast Cancer Rep, vol. 11, no. 4, pp. 303\u2013310, Dec. https:\/\/doi.org\/10.1007\/s12609-019-00334-2","DOI":"10.1007\/s12609-019-00334-2"}],"container-title":["Breast Cancer Research and Treatment"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10549-024-07302-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10549-024-07302-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10549-024-07302-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,26]],"date-time":"2024-06-26T10:35:44Z","timestamp":1719398144000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10549-024-07302-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4,25]]},"references-count":29,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2024,8]]}},"alternative-id":["7302"],"URL":"https:\/\/doi.org\/10.1007\/s10549-024-07302-0","relation":{},"ISSN":["0167-6806","1573-7217"],"issn-type":[{"type":"print","value":"0167-6806"},{"type":"electronic","value":"1573-7217"}],"subject":[],"published":{"date-parts":[[2024,4,25]]},"assertion":[{"value":"14 November 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 February 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 April 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors have no conflict of interest to declare.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Ethics approval was obtained by the Ontario Cancer Research Ethics Board.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Completion of the survey implied consent to participate.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Completion of the survey implied consent to publish aggregate data.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}}]}}